US20090098048A2 - Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor - Google Patents

Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor Download PDF

Info

Publication number
US20090098048A2
US20090098048A2 US11/597,557 US59755705A US2009098048A2 US 20090098048 A2 US20090098048 A2 US 20090098048A2 US 59755705 A US59755705 A US 59755705A US 2009098048 A2 US2009098048 A2 US 2009098048A2
Authority
US
United States
Prior art keywords
tumor
suv
tyrosine derivative
radioactive
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/597,557
Other versions
US9388122B2 (en
US20080138281A1 (en
Inventor
Kengo Sato
Hideo Tsukada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamamatsu Photonics KK
Original Assignee
Hamamatsu Photonics KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamamatsu Photonics KK filed Critical Hamamatsu Photonics KK
Assigned to HAMAMATSU PHOTONICS K.K. reassignment HAMAMATSU PHOTONICS K.K. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SATO, KENGO, TSUKADA, HIDEO
Publication of US20080138281A1 publication Critical patent/US20080138281A1/en
Publication of US20090098048A2 publication Critical patent/US20090098048A2/en
Application granted granted Critical
Publication of US9388122B2 publication Critical patent/US9388122B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present invention relates to a radioactive tyrosine derivative, a method for producing same, a labeled agent for positron imaging and an agent for assessing grade of tumor malignancy respectively consisting of a radioactive tyrosine derivative, and a method for detecting tumor.
  • [ 18 F]-2-fluoro-2-deoxy-D-glucose (hereinafter, abbreviated to [ 18 F]FDG), which is most widely used clinically at present, is a glucose analog, and its use in the diagnosis is based on the fact that the localization of [ 18 F]FDG reflects energy metabolism.
  • L-[ 11 C]methionine (hereinafter, abbreviated to L-[ 11 C]Met), a derivative of a natural amino acid, is also used in tumor diagnosis by PET, which utilizes the fact that the localization of L-[ 11 C]Met reflects amino acid metabolism (see e.g., Non-Patent Document 1).
  • [ 18 F]FDG also accumulates in inflammatory sites and so on, its specificity to tumor is not necessarily high. Moreover, in the assessment of the effect of radiotherapy, [ 18 F]FDG must be used after at least 1 month of the therapy because transient increase in [ 18 F]FDG probably caused by inflammation is exhibited immediately after the therapy. Thus, [ 18 F]FDG is not suitable for use in the assessment of therapeutic effect.
  • L-[ 11 C]Met is effective for the diagnosis of some tumors such as brain tumor and however, presents a problem of its low specificity to tumor itself.
  • an object of the present invention is to provide a labeled compound for positron imaging with high specificity to tumor and a labeled compound capable of early assessment of therapeutic effect.
  • the compound wherein R 1 is — 11 CH 3 is O—[ 11 C]methyl-D-tyrosine (hereinafter, abbreviated to D-[ 11 C]MT), and the compound wherein R 1 is —CH 2 18 F is O—[ 18 F]fluoromethyl-D-tyrosine (hereinafter, abbreviated to D-[ 18 F]FMT).
  • the compound wherein R 1 is — 11 CH 2 CH 3 is O—[ 11 C]ethyl-D-tyrosine (hereinafter, abbreviated to D-[ 11 C]ET), and the compound wherein R 1 is —CH 2 CH 2 CH 2 18 F is O—[ 18 F]fluoropropyl-D-tyrosine (hereinafter, abbreviated to D-[ 18 F]FPT).
  • D-[ 18 F]FET has been thought to be not available in tumor imaging because it has low blood-brain barrier permeability and does not accumulate in tumor tissues due to its low uptake to cancer cells (see e.g., Non-Patent Documents 2 and 3).
  • the present invention also provides a labeled agent for positron imaging consisting of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof.
  • R 2 represents any group selected from the group consisting of — 11 CH 3 , — 11 CH 2 CH 3 , —CH 2 18 F, —CH 2 CH 2 18 F, and —CH 2 CH 2 CH 2 18 F.
  • radioactive tyrosine derivative represented by the formula (I) but also the radioactive tyrosine derivative represented by the formula (II) sufficiently accumulates in tumor tissues and in addition, accumulates in a manner specific to tumor tissues. Therefore, it can be used as a labeled compound for PET.
  • a labeled agent for positron imaging with high specificity to tumor and a compound useful as a labeled agent capable of early assessment of therapeutic effect can be provided.
  • FIG. 1 is a diagram showing the accumulating amounts of L- and D-[ 11 C]Met in each organ.
  • FIG. 1 ( a ) indicates the accumulating amount by SUV
  • FIG. 1 ( b ) indicates the accumulating amount by SUV (organ)/SUV (blood);
  • FIG. 2 is a diagram showing the accumulating amounts of L- and D-[ 11 C]MT in each organ.
  • FIG. 2 ( a ) indicates the accumulating amount by SUV
  • FIG. 2 ( b ) indicates the accumulating amount by SUV (organ)/SUV (blood);
  • FIG. 4 is a diagram showing a result of planar imaging of L- and D-[ 11 C]Met administeration
  • FIG. 5 is a diagram showing a result of planar imaging of L- and D-[ 11 C]MT administeration
  • FIG. 6 is a diagram showing a result of planar imaging of L- and D-[ 18 F]FMT administeration
  • FIG. 7 is a diagram showing the relationship between the number of days elapsed after HeLa transplantation and tumor volumes
  • FIG. 9 is a diagram showing the accumulating amount (SUV (organ)/SUV (blood)) of each compound in tumor;
  • FIG. 11 is a diagram showing the accumulating amounts of L- and D-[ 18 F]FET in each organ.
  • the accumulating amount is indicated by SUV (organ)/SUV (blood);
  • FIG. 12 is a diagram showing the accumulating amounts of L- and D-[ 18 F]FPT in each organ.
  • the accumulating amount is indicated by SUV (organ)/SUV (blood); and
  • FIG. 13 is a diagram showing the accumulating amount (SUV (organ)/SUV (blood)) of each compound in tumor.
  • radioactive tyrosine derivative of the present invention is represented by the formula (I).
  • These derivatives sufficiently accumulate in tumor tissues and in addition, accumulate in a manner specific to tumor tissues. Therefore, they are useful as a labeled agent for positron imaging. Alternatively, these derivatives differ in the degree of accumulation to tumor according to the tumor proliferation rate and are therefore useful as an agent for assessing grade of tumor malignancy.
  • the compound represented by the formula (I) can be synthesized by alkylating or fluoroalkylating D-tyrosine.
  • a synthesis method thereof will be described by taking D-[ 11 C]MT and D-[ 18 F]FMT as an example.
  • D-[ 11 C]MT may be synthesized by methylating D-tyrosine.
  • reagents used in the methylation include: [ 11 C]methyl halide such as [ 11 C]methyl chloride, [ 11 C]methyl bromide, and [ 11 C]methyl iodide; and [ 11 C]methyl triflate.
  • [ 11 C]methyl iodide and [ 11 C]methyl triflate are particularly preferable because D-[ 11 C]MT can be synthesized efficiently in a short time by virtue of their high reactivity.
  • These reagents may be synthesized by a method known in the art (e.g., the method described in Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 46, p. 555-566 (2003)).
  • a reaction solvent is not particularly limited as long as it dissolves the starting material therein without reacting therewith.
  • dimethyl sulfoxide may be used.
  • the crude product can be purified by reversed-phase HPLC to obtain D-[ 11 C]MT.
  • D-[ 18 F]FMT may be synthesized by fluoromethylating D-tyrosine.
  • reagents used in the fluoromethylation include [ 18 F]FCH 2 Br and [ 18 F]fluoromethyl triflate.
  • D-[ 18 F]FMT can be synthesized efficiently in a short time by virtue of the high reactivity of these reagents.
  • These reagents may be synthesized by a method known in the art (e.g., the method described in Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 46, p. 555-566 (2003)).
  • a reaction solvent is not particularly limited as long as it dissolves the starting material therein without reacting therewith.
  • dimethyl sulfoxide may be used.
  • the crude product can be purified by reverse-phase HPLC to obtain D-[ 18 F]FMT.
  • D-[ 11 C]ET can be synthesized by ethylating D-tyrosine with [ 11 C]ethyl iodide or the like.
  • D-[ 18 F]FPT can be synthesized by fluoropropylating D-tyrosine with [ 18 F]FCH 2 CH 2 CH 2 OTs (Ts: p-toluenesulfonyl group) or the like.
  • the labeled agent for positron imaging of the present invention consists of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof. These derivatives sufficiently accumulate in tumor tissues and in addition, accumulate in a manner specific to tumor tissues. Therefore, they are useful as a labeled agent for positron imaging.
  • the radioactive tyrosine derivative represented by the formula (II) may be synthesized by a method equivalent to the synthesis methods of D-[ 11 C]MT and D-[ 18 F]FMT. Alternatively, the method described in The Journal of Nuclear Medicine, Vol. 40, No. 1, pp. 205-212, 1999 may be utilized.
  • Examples of the pharmaceutically acceptable salt include alkali metal salts (e.g., sodium salts and potassium salts), calcium salts, and amine salts (e.g., diethylamine salts).
  • Alternative examples thereof include hydrochloride, hydrogenbromide, sulfate and bisulfate, phosphate and hydrogenphosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate, and tartrate.
  • PET measurement using the radioactive tyrosine derivative represented by the formula (II) can be performed, for example, by administering the radioactive tyrosine derivative represented by the formula (II) to a subject and using a PET system (e.g., PPIS-4800 manufactured by Hamamatsu Photonics K. K.) to perform PET measurement.
  • the PET system detects annihilation photons, that is, ⁇ -rays, which are emitted by the binding between positrons released from the emitting nuclide ( 11 C or 18 F) of the administered radioactive tyrosine derivative and surrounding substance-constituting electrons.
  • the obtained measurement data may be processed, if necessary, with image reconstitution software to obtain an image.
  • the radioactive tyrosine derivative represented by the formula (II) accumulates in tumor tissues, whereas its accumulation to normal tissues is low. Therefore, the location of accumulation of the radioactive tyrosine derivative represented by the formula (II) can be determined by measuring the ⁇ -ray level or by analyzing the image. As a result, it can be judged that tumor has been formed there.
  • the agent for assessing grade of tumor malignancy of the present invention consists of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof. These derivatives differ in the degree of accumulation to tumor according to the tumor proliferation rate and are therefore useful as an agent for assessing grade of tumor malignancy.
  • the assessing grade of tumor malignancy using the radioactive tyrosine derivative represented by the formula (II) may be performed by the following procedures: the radioactive tyrosine derivative represented by the formula (II) is administered to a subject to perform PET measurement in the same way as in the method described above.
  • the ⁇ -ray level or image of a tumor site may be analyzed to assess the malignancy of the tumor.
  • the radioactive tyrosine derivative represented by the formula (II) has the property of easily accumulating in tumor tissues with high proliferation rates. Therefore, the tumor, when having a high ⁇ -ray level, can be judged as having high malignancy (high proliferation rate).
  • the radioactive tyrosine derivative represented by the formula (II) is first administered to a subject.
  • An administration method thereof is usually intravenous administration.
  • a radiation dose of each tissue of the subject is measured.
  • the radiation dose measurement may be performed by the PET measurement described above.
  • a tissue with a relatively large radiation dose is detected as a tumor tissue through comparison of the radiation dose of each tissue.
  • SUV standardized uptake value
  • particularly SUV (tissue)/SUV (blood) a relative value with respect to the radiation dose of blood
  • a tissue with a relatively large radiation dose may be identified from an image.
  • D-tyrosine (1 mg) was supplemented with 10% sodium hydroxide aqueous solution (4.41 ⁇ l) and further with dimethyl sulfoxide (0.3 mL) to prepare a stock solution.
  • the [ 11 C]methyl iodide produced by the method was bubbled into the stock solution and thereby trapped therein. Then, the reaction vessel was hermetically sealed, and reaction was performed at 80° C. for 3 minutes.
  • the crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 8 minutes was collected and concentrated under reduced pressure to purify D-[ 11 C]MT.
  • the residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22- ⁇ m membrane filter to obtain a solution of 2 to 5 GBq of D-[ 11 C]MT in saline (radiochemical purity: 97% or higher).
  • D-tyrosine (1 mg) was supplemented with 10% sodium hydroxide aqueous solution (4.41 ⁇ l) and further with dimethyl sulfoxide (0.3 mL) to prepare a stock solution.
  • the [ 18 F]FCH 2 Br produced by the method was bubbled into the stock solution and thereby trapped therein. Then, the reaction vessel was hermetically sealed, and reaction was performed at 80° C. for 5 minutes.
  • the crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 9 minutes was collected and concentrated under reduced pressure to purify D-[ 18 F]FMT.
  • the residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22- ⁇ m membrane filter to obtain a solution of 1 to 3 GBq of D-[ 18 F]FMT in saline (radiochemical purity: 97% or higher).
  • L-[ 11 C]MT was synthesized in the same way as in the method described in Example 1 except that L-tyrosine was used as a starting material instead of D-tyrosine.
  • D-[ 18 F]FMT was synthesized in the same way as in the method described in Example 1 except that L-tyrosine was used as a starting material instead of D-tyrosine.
  • Human cervical cancer HeLa cells (cell strain: 15S3D) were subcutaneously transplanted at 5 ⁇ 10 6 cells/mouse to the thighs of 7-week-old nude mice (BALB/cA Jcl-nu, Clea Japan, Inc). After 2 weeks of the transplantation (9 weeks of age), the compounds of Examples 1 to 2 and the compounds of Comparative Examples 1 to 7 were administered through the tail veins at 10 MBq (the compounds of Example 1 and Comparative Examples 1, 3, 4, and 6) or 1 MBq (the compounds of Example 2 and Comparative Examples 2, 5, and 7).
  • mice After 1 hour of the administration, the mice were decapitated to collect each organ (blood, heart, lung, liver, kidney, spleen, muscle, bone, small intestine, gastrointestinal tract, pancreas, brain, and tumor). The radioactivity of each organ was measured with an automatic gamma counter, and the weight of each organ was measured. SUV (standardized uptake value) that served as an index of the accumulating amounts of the administered compounds was determined. Furthermore, to correct the accumulating amounts, SUV (organ)/SUV (blood) was determined by dividing the SUV of each organ by the SUV of blood. The obtained results are shown in FIGS. 1 to 3 .
  • FIG. 1 is a diagram showing the accumulating amounts of L- and D-[ 11 C]Met in each organ.
  • FIG. 1 ( a ) indicates the accumulating amount by SUV
  • FIG. 1 ( b ) indicates the accumulating amount by SUV (organ)/SUV (blood).
  • FIG. 1 ( b ) indicates the accumulating amount by SUV (organ)/SUV (blood).
  • FIG. 2 is a diagram showing the accumulating amounts of L- and D-[ 11 C]MT in each organ.
  • FIG. 2 ( a ) indicates the accumulating amount by SUV
  • FIG. 2 ( b ) indicates the accumulating amount by SUV (organ)/SUV (blood).
  • FIG. 2 ( b ) indicates the accumulating amount by SUV (organ)/SUV (blood).
  • the D-form had a higher value of SUV (organ: tumor)/SUV (blood) than the L-form Moreover, the ratio of accumulation to the pancreas to accumulation to the tumor indicated by SUV (organ)/SUV (blood) was shown to be lower in the D-form than in the L-form. Thus, it was suggested that the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
  • FIG. 3 is a diagram showing the accumulating amounts of L- and D-[ 18 F]FMT in each organ.
  • FIG. 3 ( a ) indicates the accumulating amount by SUV
  • FIG. 3 ( b ) indicates the accumulating amount by SUV (organ)/SUV (blood).
  • the D-form had a higher value of SUV (organ: tumor)/SUV (blood) than the L-form and was shown to have particularly high specificity to the tumor.
  • the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
  • FIG. 5 is a diagram showing a result of planar measurement of L- and D-[ 11 C]MT administered. The accumulation of both the L- and D-forms was observed in the tumor site. Moreover, the D-form was confirmed to accumulate in a manner specific to the tumor as compared with the L-form.
  • FIG. 6 is a diagram showing a result of planar measurement of L- and D-[ 18 F]FMT administered. The accumulation of both the L- and D-forms was observed in the tumor site. Moreover, the D-form was confirmed to accumulate in a manner specific to the tumor as compared with the L-form.
  • the HeLa-K- and HeLa-B-transplanted mice when becoming 9 week old after 2 weeks and 4 weeks of the transplantation, respectively, were used in the experiment.
  • tumor size was daily measured.
  • Doubling time (DT) was calculated according to the calculation formula: DT-t ⁇ log 2 (V1/V0) proposed by Schwartz, wherein t denotes the number of days required for the tumor volume to reach V1 (mm 3 ) from V0 (mm 3 ), and the volume (mm 3 ) was calculated according to 1 ⁇ 2 ⁇ length (mm) ⁇ width 2 (mm 2 ) from the major axis of the tumor.
  • HeLa-K was a cancer cell that had a high proliferation rate
  • HeLa-B was a cancer cell that had a low proliferation rate.
  • the doubling times of HeLa-K and HeLa-B calculated from FIG. 7 were 4.4 days and 11.0 days, respectively.
  • mice were administered through the tail veins with [ 18 F]FDG, [ 11 C]choline, [ 18 F]FLT, L- and D-[ 11 C]Met, and L- and D-[ 11 C]MT at 1 MBq ([ 18 F]FDG and [ 18 F]FLT) or 10 MBq ([ 11 C]choline, L- and D-[ 11 C]Met, and L- and D-[ 11 C]MT).
  • the mice were decapitated to collect blood and tumor.
  • the radioactivities of the blood and tumor were measured with an automatic gamma counter, their weights were measured, and SUV was determined.
  • SUV organ/SUV (blood) was determined by dividing the SUV of the tumor by the SUV of the blood. The obtained results are shown in FIGS. 8 to 9 .
  • FIGS. 8 and 9 are respectively diagrams showing the accumulating amount of each compound in blood and tumor.
  • FIG. 8 indicates the accumulating amount by SUV
  • FIG. 9 indicates the accumulating amount by SUV (organ)/SUV (blood).
  • D-[ 11 C]MT accumulated more in HeLa-K exhibiting faster proliferation.
  • the difference in the degree of accumulation depending on the difference in proliferation rate was remarkably large for D-[ 11 C]MT as compared with L-[ 11 C]MT and D-[ 11 C]Met.
  • [ 18 F]FDG and L-[ 11 C]Met the difference in the degree of accumulation depending on the difference in proliferation rate was not detected.
  • D-[ 11 C]MT is considered to be excellent for the assessment of therapeutic effect on tumor as compared with existing labeled compounds.
  • D-tyrosine (1 mg) was supplemented with 10% sodium hydroxide aqueous solution (4.41 ⁇ l) and further with dimethyl sulfoxide (0.3 mL) to prepare a material solution.
  • the [ 11 C]ethyl iodide produced by the method was bubbled into the material solution and thereby trapped therein. Then, the reaction vessel was hermetically sealed, and reaction was performed at 80° C. for 3 minutes.
  • the crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 13 minutes was collected and concentrated under reduced pressure to purify D-[ 11 C]ET.
  • the residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22- ⁇ m membrane filter to obtain a solution of 0.8 to 1.5 GBq of D-[ 11 C]ET in saline (radiochemical purity: 99% or higher).
  • D-tyrosine (3 mg) was supplemented with 10% sodium hydroxide aqueous solution (13.2 ⁇ l) and further with dimethyl sulfoxide (0.3 mL) to prepare a material solution.
  • the material solution was added to the [ 18 F]FCH 2 CH 2 OTs produced by the method. Then, the reaction vessel was hermetically sealed, and reaction was performed at 125° C. for 10 minutes.
  • the crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 9 minutes was collected and concentrated under reduced pressure to purify D-[ 18 F]FET.
  • D-tyrosine (3 mg) was supplemented with 10% sodium hydroxide aqueous solution (13.2 ⁇ l) and further with dimethyl sulfoxide (0.3 mL) to prepare a material solution.
  • the material solution was added to the [ 18 F]FCH 2 CH 2 CH 2 OTs produced by the method. Then, the reaction vessel was hermetically sealed, and reaction was performed at 125° C. for 10 minutes.
  • the crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 17 minutes was collected and concentrated under reduced pressure to purify D-[ 18 F]FPT.
  • the residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22- ⁇ m membrane filter to obtain a solution of 0.2 to 0.6 GBq of D-[ 18 F]FPT in saline (radiochemical purity: 99% or higher).
  • L-[ 11 C]ET was synthesized in the same way as in the method described in Example 3 except that L-tyrosine was used as a material instead of D-tyrosine.
  • L-[ 18 F]FET was synthesized in the same way as in the method described in Example 4 except that L-tyrosine was used as a material instead of D-tyrosine.
  • L-[ 18 F]FPT was synthesized in the same way as in the method described in Example 5 except that L-tyrosine was used as a material instead of D-tyrosine.
  • FIG. 10 is a diagram showing the accumulating amounts of L- and D-[ 11 C]ET in each organ.
  • the accumulating amount is indicated by SUV (organ)/SUV (blood).
  • SUV (organ)/SUV (blood) the accumulation of L- and D-[ 11 C]MT was observed in the tumor, whereas their accumulation was low in the normal tissues except for the pancreas and was specific to the tumor.
  • the D-form had a similar value of SUV (organ: tumor)/SUV (blood) comparable to that of the L-form.
  • the ratio of accumulation to the pancreas to accumulation to the tumor indicated by SUV (organ)/SUV (blood) was shown to be lower in the D-form than in the L-form.
  • the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
  • FIG. 11 is a diagram showing the accumulating amounts of L- and D-[ 18 F]FET in each organ.
  • the accumulating amount is indicated by SUV (organ)/SUV (blood).
  • SUV (organ)/SUV (blood) the accumulation of L- and D-[ 18 F]FET was observed in the tumor, whereas their accumulation was low in the normal tissues except for the pancreas and was specific to the tumor.
  • the D-form had a higher value of SUV (organ: tumor)/SUV (blood) than the L-form and was shown to have particularly high specificity to the tumor.
  • the ratio of accumulation to the pancreas to accumulation to the tumor indicated by SUV (organ)/SUV (blood) was shown to be lower in the D-form than in the L-form.
  • the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
  • FIG. 12 is a diagram showing the accumulating amounts of L- and D-[ 18 F]FPT in each organ.
  • the accumulating amount is indicated by SUV (organ)/SUV (blood).
  • SUV (organ)/SUV (blood) the accumulation of L- and D-[ 18 F]FPT was observed in the tumor, whereas their accumulation was low in the normal tissues except for the pancreas and bone and was specific to the tumor.
  • the D-form had a similar value of SUV (organ: tumor)/SUV (blood) comparable to that of the L-form.
  • the ratio of accumulation to the pancreas to accumulation to the tumor indicated by SUV (organ)/SUV (blood) was shown to be lower in the D-form than in the L-form.
  • the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
  • mice HeLa-K- and HeLa-B-transplanted nude mice were administered through the tail veins with L- and D-[ 11 C]ET, L- and D-[ 18 F]FMT, L- and D-[ 18 F]FET, and L- and D-[ 18 F]FPT at 10 MBq (L- and D-[ 11 C]ET) or 1 MBq (the others).
  • the mice were decapitated to collect blood and tumor.
  • the radioactivities of the blood and tumor were measured with an automatic gamma counter, their weights were measured, and SUV was determined.
  • SUV organ
  • SUV blood
  • FIG. 13 is a diagram showing the accumulating amount of each compound in tumor.
  • the accumulating amount is indicated by SUV (organ)/SUV (blood).
  • SUV organ
  • SUV blood
  • all of the compounds accumulated more in HeLa-K exhibiting faster proliferation.
  • the difference in the degree of accumulation of D-[ 18 F]FMT depending on the difference in proliferation rate was remarkably large as compared with D-[ 18 F]FMT.
  • these compounds are considered to be excellent for the assessment of therapeutic effect on tumor as compared with existing labeled compounds.
  • the present invention allows for tumor diagnosis by PET and particularly allows for the early assessment of the therapeutic effect of radiotherapy and so on.

Abstract

It is intended to provide a radioactive tyrosine derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof:
Figure US20090098048A2-20090416-C00001
wherein R1 represents a group selected from the group consisting of —11CH3, —11CH2CH3, —CH2 18F, and —CH2CH2CH2 18F.

Description

    TECHNICAL FIELD
  • The present invention relates to a radioactive tyrosine derivative, a method for producing same, a labeled agent for positron imaging and an agent for assessing grade of tumor malignancy respectively consisting of a radioactive tyrosine derivative, and a method for detecting tumor.
    • BACKGROUND ART
  • Tumor diagnosis by PET (positron emission tomography) exploits the phenomenon where tumor tissues proliferate rapidly as compared with normal tissues. For example, [18F]-2-fluoro-2-deoxy-D-glucose (hereinafter, abbreviated to [18F]FDG), which is most widely used clinically at present, is a glucose analog, and its use in the diagnosis is based on the fact that the localization of [18F]FDG reflects energy metabolism. Alternatively, L-[11C]methionine (hereinafter, abbreviated to L-[11C]Met), a derivative of a natural amino acid, is also used in tumor diagnosis by PET, which utilizes the fact that the localization of L-[11C]Met reflects amino acid metabolism (see e.g., Non-Patent Document 1).
    • [Non-Patent Document 1] The Journal of Nuclear Medicine, 1991, Vol. 32, No. 6, p. 1211-1218
    • [Non-Patent Document 2] The Journal of Nuclear Medicine, 1999, Vol. 40, No. 1, p. 205-212
    • [Non-Patent Document 3] The Journal of Nuclear Medicine, 1999, Vol. 40, No. 8, p. 1367-1373
    DISCLOSURE OF THE INVENTION Problem to be Solved by the Invention
  • However, since [18F]FDG also accumulates in inflammatory sites and so on, its specificity to tumor is not necessarily high. Moreover, in the assessment of the effect of radiotherapy, [18F]FDG must be used after at least 1 month of the therapy because transient increase in [18F]FDG probably caused by inflammation is exhibited immediately after the therapy. Thus, [18F]FDG is not suitable for use in the assessment of therapeutic effect. On the other hand, L-[11C]Met is effective for the diagnosis of some tumors such as brain tumor and however, presents a problem of its low specificity to tumor itself.
  • Thus, an object of the present invention is to provide a labeled compound for positron imaging with high specificity to tumor and a labeled compound capable of early assessment of therapeutic effect.
    • Means to Solve the Problem
  • To attain the object, the present invention provides a radioactive tyrosine derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof.
    Figure US20090098048A2-20090416-C00002
    In the formula, R1 represents a group selected from the group consisting of —11CH3, —11CH2CH3, —CH2 18F, and —CH2CH2CH2 18F.
  • In this context, the compound wherein R1 is —11CH3 is O—[11C]methyl-D-tyrosine (hereinafter, abbreviated to D-[11C]MT), and the compound wherein R1 is —CH2 18F is O—[18F]fluoromethyl-D-tyrosine (hereinafter, abbreviated to D-[18F]FMT). Alternatively, the compound wherein R1 is —11CH2CH3 is O—[11C]ethyl-D-tyrosine (hereinafter, abbreviated to D-[11C]ET), and the compound wherein R1 is —CH2CH2CH2 18F is O—[18F]fluoropropyl-D-tyrosine (hereinafter, abbreviated to D-[18F]FPT).
  • O—[18F]fluoroethyl-D-tyrosine (hereinafter, abbreviated to D-[18F]FET) represented by the formula (III) has already been known as a compound analogous to these radioactive tyrosine derivatives (see e.g., Non-Patent Documents 2 and 3).
    Figure US20090098048A2-20090416-C00003
  • However, D-[18F]FET has been thought to be not available in tumor imaging because it has low blood-brain barrier permeability and does not accumulate in tumor tissues due to its low uptake to cancer cells (see e.g., Non-Patent Documents 2 and 3).
  • However, the present inventors have found that the radioactive tyrosine derivative represented by the formula (I) or the pharmaceutically acceptable salt thereof sufficiently accumulates in tumor tissues in sharp contrast to the behavior described in Non-Patent Documents 2 and 3 and in addition, accumulates in a manner specific to tumor tissues, and have shown that it can be used as a labeled compound for PET.
  • The radioactive tyrosine derivative represented by the formula (I) or the pharmaceutically acceptable salt thereof that possesses such excellent properties may efficiently and steadily be obtained by alkylating or fluoroalkylating D-tyrosine.
  • The present invention also provides a labeled agent for positron imaging consisting of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof.
    Figure US20090098048A2-20090416-C00004
    In the formula, R2 represents any group selected from the group consisting of —11CH3, —11CH2CH3, —CH2 18F, —CH2CH2 18F, and —CH2CH2CH2 18F.
  • Not only the radioactive tyrosine derivative represented by the formula (I) but also the radioactive tyrosine derivative represented by the formula (II) sufficiently accumulates in tumor tissues and in addition, accumulates in a manner specific to tumor tissues. Therefore, it can be used as a labeled compound for PET.
  • The present invention also provides an agent for assessing grade of tumor malignancy consisting of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof. The radioactive tyrosine derivative represented by the formula (II) or the pharmaceutically acceptable salt thereof differs in the degree of accumulation to tumor according to the tumor proliferation rate and as such, can also be used as an agent for assessing grade of tumor malignancy. Unlike [18F]FDG, the radioactive tyrosine derivative represented by the formula (II) is hardly affected by inflammation and may therefore be used in the assessment of therapeutic effect immediately after therapy.
  • The present invention further provides a method for detecting tumor comprising: a step of administering a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof to a subject; a step of measuring a radiation dose of each tissue of the subject; and a detection step of detecting a tissue with a relatively large radiation dose as a tumor tissue through comparisons of the radiation dose of each tissue. The radioactive tyrosine derivative represented by the formula (II) or the pharmaceutically acceptable salt thereof hardly accumulates in normal tissues and easily accumulates in tumor tissues. By use of this property, tumor may be detected. It is preferred that at the detection step, a tissue with a relatively large radiation dose with respect to the radiation dose of blood should be detected as a tumor tissue. This is because the difference between normal tissues and tumor tissues can be defined clearly by using the radiation dose of blood as a reference.
    • EFFECT OF THE INVENTION
  • A labeled agent for positron imaging with high specificity to tumor and a compound useful as a labeled agent capable of early assessment of therapeutic effect can be provided.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a diagram showing the accumulating amounts of L- and D-[11C]Met in each organ. FIG. 1(a) indicates the accumulating amount by SUV, and FIG. 1(b) indicates the accumulating amount by SUV (organ)/SUV (blood);
  • FIG. 2 is a diagram showing the accumulating amounts of L- and D-[11C]MT in each organ. FIG. 2(a) indicates the accumulating amount by SUV, and FIG. 2(b) indicates the accumulating amount by SUV (organ)/SUV (blood);
  • FIG. 3 is a diagram showing the accumulating amounts of L- and D-[18F]FMT in each organ. FIG. 3(a) indicates the accumulating amount by SUV, and FIG. 3(b) indicates the accumulating amount by SUV (organ)/SUV (blood);
  • FIG. 4 is a diagram showing a result of planar imaging of L- and D-[11C]Met administeration;
  • FIG. 5 is a diagram showing a result of planar imaging of L- and D-[11C]MT administeration;
  • FIG. 6 is a diagram showing a result of planar imaging of L- and D-[18F]FMT administeration;
  • FIG. 7 is a diagram showing the relationship between the number of days elapsed after HeLa transplantation and tumor volumes;
  • FIG. 8 is a diagram showing the accumulating amount (SUV) of each compound in blood and tumor;
  • FIG. 9 is a diagram showing the accumulating amount (SUV (organ)/SUV (blood)) of each compound in tumor;
  • FIG. 10 is a diagram showing the accumulating amounts of L- and D-[11C]ET in each organ. The accumulating amount is indicated by SUV (organ)/SUV (blood);
  • FIG. 11 is a diagram showing the accumulating amounts of L- and D-[18F]FET in each organ. The accumulating amount is indicated by SUV (organ)/SUV (blood);
  • FIG. 12 is a diagram showing the accumulating amounts of L- and D-[18F]FPT in each organ. The accumulating amount is indicated by SUV (organ)/SUV (blood); and
  • FIG. 13 is a diagram showing the accumulating amount (SUV (organ)/SUV (blood)) of each compound in tumor.
    • DESCRIPTION OF REFERENCE NUMERAL
      • 1: tumor site
    BEST MODE FOR CARRYING OUT THE INVENTION
  • Hereinafter, the preferable embodiments of the present invention will be described in detail.
  • First, a radioactive tyrosine derivative of the present invention will be described. The radioactive tyrosine derivative of the present invention is represented by the formula (I). These derivatives sufficiently accumulate in tumor tissues and in addition, accumulate in a manner specific to tumor tissues. Therefore, they are useful as a labeled agent for positron imaging. Alternatively, these derivatives differ in the degree of accumulation to tumor according to the tumor proliferation rate and are therefore useful as an agent for assessing grade of tumor malignancy.
  • The compound represented by the formula (I) can be synthesized by alkylating or fluoroalkylating D-tyrosine. Hereinafter, a synthesis method thereof will be described by taking D-[11C]MT and D-[18F]FMT as an example.
  • D-[11C]MT may be synthesized by methylating D-tyrosine. Examples of reagents used in the methylation include: [11C]methyl halide such as [11C]methyl chloride, [11C]methyl bromide, and [11C]methyl iodide; and [11C]methyl triflate. Among them, [11C]methyl iodide and [11C]methyl triflate are particularly preferable because D-[11C]MT can be synthesized efficiently in a short time by virtue of their high reactivity. These reagents may be synthesized by a method known in the art (e.g., the method described in Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 46, p. 555-566 (2003)).
  • A reaction solvent is not particularly limited as long as it dissolves the starting material therein without reacting therewith. For example, dimethyl sulfoxide may be used. After the termination of reaction, the crude product can be purified by reversed-phase HPLC to obtain D-[11C]MT.
  • D-[18F]FMT may be synthesized by fluoromethylating D-tyrosine. Examples of reagents used in the fluoromethylation include [18F]FCH2Br and [18F]fluoromethyl triflate. D-[18F]FMT can be synthesized efficiently in a short time by virtue of the high reactivity of these reagents. These reagents may be synthesized by a method known in the art (e.g., the method described in Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 46, p. 555-566 (2003)).
  • A reaction solvent is not particularly limited as long as it dissolves the starting material therein without reacting therewith. For example, dimethyl sulfoxide may be used. After the termination of reaction, the crude product can be purified by reverse-phase HPLC to obtain D-[18F]FMT.
  • Likewise, D-[11C]ET can be synthesized by ethylating D-tyrosine with [11C]ethyl iodide or the like. Alternatively, D-[18F]FPT can be synthesized by fluoropropylating D-tyrosine with [18F]FCH2CH2CH2OTs (Ts: p-toluenesulfonyl group) or the like.
  • Examples of a pharmaceutically acceptable salt of the radioactive tyrosine derivative of the present invention include alkali metal salts (e.g., sodium salts and potassium salts), calcium salts, and amine salts (e.g., diethylamine salts). Alternative examples thereof include hydrochloride, hydrobromide, sulfate and bisulfate, phosphate and hydrogenphosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate, and tartrate.
  • Next, a labeled agent for positron imaging of the present invention will be described. The labeled agent for positron imaging of the present invention consists of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof. These derivatives sufficiently accumulate in tumor tissues and in addition, accumulate in a manner specific to tumor tissues. Therefore, they are useful as a labeled agent for positron imaging.
  • The radioactive tyrosine derivative represented by the formula (II) may be synthesized by a method equivalent to the synthesis methods of D-[11C]MT and D-[18F]FMT. Alternatively, the method described in The Journal of Nuclear Medicine, Vol. 40, No. 1, pp. 205-212, 1999 may be utilized.
  • Examples of the pharmaceutically acceptable salt include alkali metal salts (e.g., sodium salts and potassium salts), calcium salts, and amine salts (e.g., diethylamine salts). Alternative examples thereof include hydrochloride, hydrogenbromide, sulfate and bisulfate, phosphate and hydrogenphosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate, and tartrate.
  • PET measurement using the radioactive tyrosine derivative represented by the formula (II) can be performed, for example, by administering the radioactive tyrosine derivative represented by the formula (II) to a subject and using a PET system (e.g., PPIS-4800 manufactured by Hamamatsu Photonics K. K.) to perform PET measurement. The PET system detects annihilation photons, that is, γ-rays, which are emitted by the binding between positrons released from the emitting nuclide (11C or 18F) of the administered radioactive tyrosine derivative and surrounding substance-constituting electrons. Furthermore, the obtained measurement data may be processed, if necessary, with image reconstitution software to obtain an image.
  • The radioactive tyrosine derivative represented by the formula (II) accumulates in tumor tissues, whereas its accumulation to normal tissues is low. Therefore, the location of accumulation of the radioactive tyrosine derivative represented by the formula (II) can be determined by measuring the γ-ray level or by analyzing the image. As a result, it can be judged that tumor has been formed there.
  • Next, an agent for assessing grade of tumor malignancy of the present invention will be described. The agent for assessing grade of tumor malignancy of the present invention consists of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof. These derivatives differ in the degree of accumulation to tumor according to the tumor proliferation rate and are therefore useful as an agent for assessing grade of tumor malignancy.
  • The assessing grade of tumor malignancy using the radioactive tyrosine derivative represented by the formula (II) may be performed by the following procedures: the radioactive tyrosine derivative represented by the formula (II) is administered to a subject to perform PET measurement in the same way as in the method described above. The γ-ray level or image of a tumor site may be analyzed to assess the malignancy of the tumor. Namely, the radioactive tyrosine derivative represented by the formula (II) has the property of easily accumulating in tumor tissues with high proliferation rates. Therefore, the tumor, when having a high γ-ray level, can be judged as having high malignancy (high proliferation rate).
  • Therapeutic effect may be assessed by performing PET measurement using the agent for assessing grade of tumor malignancy of the present invention before and after therapy such as radiotherapy. Namely, when the γ-ray level of a tumor site is decreased after therapy, it can be judged that the therapy has suppressed the tumor proliferation rate and exerted sufficient therapeutic effect.
  • Finally, a method for detecting tumor of the present invention will be described. The method for detecting tumor of the present invention comprises: the step of administering a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof to a subject; the step of measuring a radiation dose of each tissue of the subject; and the detection step of detecting a tissue with a relatively large radiation dose as a tumor tissue through comparison of the radiation dose of each tissue.
  • To detect tumor, the radioactive tyrosine derivative represented by the formula (II) is first administered to a subject. An administration method thereof is usually intravenous administration. Next, a radiation dose of each tissue of the subject is measured. The radiation dose measurement may be performed by the PET measurement described above. Then, a tissue with a relatively large radiation dose is detected as a tumor tissue through comparison of the radiation dose of each tissue. It is preferred that SUV (standardized uptake value), particularly SUV (tissue)/SUV (blood) (a relative value with respect to the radiation dose of blood), should be used in the comparison. Alternatively, a tissue with a relatively large radiation dose may be identified from an image.
    • EXAMPLES
  • Hereinafter, the present invention will be described in detail with reference to Examples. However, the present invention is not intended to be limited to these Examples.
    • Example 1 D-[11C]MT Synthesis
  • At first, [11C]methyl iodide was synthesized by the following method: a cyclotron was used to produce [11C]carbon dioxide by bombarding a nitrogen gas filled to a target with proton beams (18 MeV, 20 μA). The produced [11C]carbon dioxide was bubbled into a cooled tetrahydrofuran solution (0.5 mL) of 0.1 μM lithium aluminum hydride to reduce the [11C]carbon dioxide to [11C]methanol. To this solution was added with 0.5 mL of hydroiodic acid to produce [11C]methyl iodide.
  • D-tyrosine (1 mg) was supplemented with 10% sodium hydroxide aqueous solution (4.41 μl) and further with dimethyl sulfoxide (0.3 mL) to prepare a stock solution. The [11C]methyl iodide produced by the method was bubbled into the stock solution and thereby trapped therein. Then, the reaction vessel was hermetically sealed, and reaction was performed at 80° C. for 3 minutes. The crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 8 minutes was collected and concentrated under reduced pressure to purify D-[11C]MT.
  • HPLC Conditions
  • Column: YMC-Pack ODS-A (10×250 mm) (YMC Co., Ltd.)
  • Mobile phase: ethanol:acetic acid:water=100:25:875
  • Flow rate: 4 mL/min
  • Detection wavelength: 280 nm
  • The residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22-μm membrane filter to obtain a solution of 2 to 5 GBq of D-[11C]MT in saline (radiochemical purity: 97% or higher).
    • Example 2 D-[18F]FMT Synthesis
  • At first, [18F]FCH2Br was synthesized in the same way as in the method described in Radiation and Isotopes, Vol. 57, pp. 347-352, 2002.
  • D-tyrosine (1 mg) was supplemented with 10% sodium hydroxide aqueous solution (4.41 μl) and further with dimethyl sulfoxide (0.3 mL) to prepare a stock solution. The [18F]FCH2Br produced by the method was bubbled into the stock solution and thereby trapped therein. Then, the reaction vessel was hermetically sealed, and reaction was performed at 80° C. for 5 minutes. The crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 9 minutes was collected and concentrated under reduced pressure to purify D-[18F]FMT.
  • HPLC Conditions
  • Column: YMC-Pack ODS-A (10×250 mm) (YMC Co., Ltd.)
  • Mobile phase: ethanol:acetic acid:water=100:25:875
  • Flow rate: 4 mL/min
  • Detection wavelength: 280 nm
  • The residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22-μm membrane filter to obtain a solution of 1 to 3 GBq of D-[18F]FMT in saline (radiochemical purity: 97% or higher).
    • Comparative Example 1 O—[11C]methyl-L-tyrosine (L-[11C]MT) Synthesis
  • L-[11C]MT was synthesized in the same way as in the method described in Example 1 except that L-tyrosine was used as a starting material instead of D-tyrosine.
    • Comparative Example 2 O—[18F]fluoromethyl-L-tyrosine (D-[18F]FMT) Synthesis
  • D-[18F]FMT was synthesized in the same way as in the method described in Example 1 except that L-tyrosine was used as a starting material instead of D-tyrosine.
    • Comparative Examples 3 to 7 Synthesis of Additional Known PET Labeled Compounds
  • L- and D-[11C]Met (Comparative Examples 3 and 4) were synthesized by the method described in The Journal of Nuclear Medicine, Vol. 28, pp. 1037-1040, 1987. [18F]FDG (Comparative Example 5) was synthesized by the method described in The Journal of Nuclear Medicine, Vol. 27, pp. 235-238, 1986. [11C]choline (Comparative Example 6) was synthesized by the method described in The Journal of Nuclear Medicine, Vol. 38, pp. 842-847, 1997. 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT; Comparative Example 7) was synthesized by the method described in Journal of Radioanalytical and Nuclear Chemistry, Vol. 243, pp. 843-846, 2000.
    • Test Example 1 Measurement of Organ Distribution in Cancer-Bearing Mice
  • Human cervical cancer HeLa cells (cell strain: 15S3D) were subcutaneously transplanted at 5×106 cells/mouse to the thighs of 7-week-old nude mice (BALB/cA Jcl-nu, Clea Japan, Inc). After 2 weeks of the transplantation (9 weeks of age), the compounds of Examples 1 to 2 and the compounds of Comparative Examples 1 to 7 were administered through the tail veins at 10 MBq (the compounds of Example 1 and Comparative Examples 1, 3, 4, and 6) or 1 MBq (the compounds of Example 2 and Comparative Examples 2, 5, and 7). After 1 hour of the administration, the mice were decapitated to collect each organ (blood, heart, lung, liver, kidney, spleen, muscle, bone, small intestine, gastrointestinal tract, pancreas, brain, and tumor). The radioactivity of each organ was measured with an automatic gamma counter, and the weight of each organ was measured. SUV (standardized uptake value) that served as an index of the accumulating amounts of the administered compounds was determined. Furthermore, to correct the accumulating amounts, SUV (organ)/SUV (blood) was determined by dividing the SUV of each organ by the SUV of blood. The obtained results are shown in FIGS. 1 to 3.
  • FIG. 1 is a diagram showing the accumulating amounts of L- and D-[11C]Met in each organ. FIG. 1(a) indicates the accumulating amount by SUV, and FIG. 1(b) indicates the accumulating amount by SUV (organ)/SUV (blood). As can be seen from the result shown in FIG. 1(b), the accumulation of L- and D-[11C]Met was observed in the tumor and however, was also high in the normal tissues (particularly, liver, kidney, spleen, intestine, and pancreas). Thus, L- and D-[11C]Met were shown to be unsuitable for tumor diagnosis because of their low specificity to tumor.
  • FIG. 2 is a diagram showing the accumulating amounts of L- and D-[11C]MT in each organ. FIG. 2(a) indicates the accumulating amount by SUV, and FIG. 2(b) indicates the accumulating amount by SUV (organ)/SUV (blood). As can be seen from the result shown in FIG. 2(b), the accumulation of L- and D-[11C]MT was observed in the tumor, whereas their accumulation was low in the normal tissues except for the pancreas and was specific to the tumor. Furthermore, the D-form had a higher value of SUV (organ: tumor)/SUV (blood) than the L-form Moreover, the ratio of accumulation to the pancreas to accumulation to the tumor indicated by SUV (organ)/SUV (blood) was shown to be lower in the D-form than in the L-form. Thus, it was suggested that the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
  • FIG. 3 is a diagram showing the accumulating amounts of L- and D-[18F]FMT in each organ. FIG. 3(a) indicates the accumulating amount by SUV, and FIG. 3(b) indicates the accumulating amount by SUV (organ)/SUV (blood). As can be seen from the result shown in FIG. 3(b), the accumulation of L- and D-[11C]MT was observed in the tumor, whereas their accumulation was low in the normal tissues except for the pancreas and was specific to the tumor. Furthermore, the D-form had a higher value of SUV (organ: tumor)/SUV (blood) than the L-form and was shown to have particularly high specificity to the tumor. Thus, it was suggested that the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
    • Test Example 2 Planar Measurement in Cancer-Bearing Mice
  • Nude mice (BALB/cA Jcl-nu) into which HeLa had been transplanted in the same way as in Test Example 1 were administered through the tail veins with the compounds of Examples 1 to 2 and the compounds of Comparative Examples 1 to 7 at 2.5 MBq. Measurement was performed (1 minute×60 frames) for 60 minutes immediately after the compound administration by use of a planar imaging system (PPIS-4800 manufactured by Hamamatsu Photonics K. K.) and indicated by images each comprising 10 frames integrated. The results obtained by the planar measurement of each administered compound are shown in FIGS. 4 to 6.
  • FIG. 4 is a diagram showing a result of planar measurement of L- and D-[11C]Met administered. The accumulation of both the L- and D-forms was observed in the tumor site and however, was significantly stronger in the normal tissues. Thus, they were shown to be unsuitable for tumor imaging.
  • FIG. 5 is a diagram showing a result of planar measurement of L- and D-[11C]MT administered. The accumulation of both the L- and D-forms was observed in the tumor site. Moreover, the D-form was confirmed to accumulate in a manner specific to the tumor as compared with the L-form.
  • FIG. 6 is a diagram showing a result of planar measurement of L- and D-[18F]FMT administered. The accumulation of both the L- and D-forms was observed in the tumor site. Moreover, the D-form was confirmed to accumulate in a manner specific to the tumor as compared with the L-form.
    • Test Example 3 Relationship Between Tumor Proliferation Rate and Degree of Accumulation of Labeled Compound for Positron Imaging
  • HeLa cells differing in cell growth rate were transplanted to nude mice (BALB/cA Jcl-nu) to examine the accumulation to tumor of the compounds of Examples 1 to 2 and the compounds of Comparative Examples 1 to 7 administered to the mice. HeLa-K (cell strain: 15S3D) and HeLa-B (Health Science Research Resources Bank: JCRB9004) were subcutaneously transplanted at 5×106 cells/mouse and 2×107 cells/mouse, respectively, to the thighs of female BALB/cA Jcl-nu nude mice (HeLa-K: 7-week-old mice, HeLa-B: 5-week-old mice). The HeLa-K- and HeLa-B-transplanted mice, when becoming 9 week old after 2 weeks and 4 weeks of the transplantation, respectively, were used in the experiment. To examine the relationship between the accumulation of each labeled compound in the cancer-bearing mice and the proliferation rate of the tumor tissue, tumor size was daily measured. Doubling time (DT) was calculated according to the calculation formula: DT-t×log 2 (V1/V0) proposed by Schwartz, wherein t denotes the number of days required for the tumor volume to reach V1 (mm3) from V0 (mm3), and the volume (mm3) was calculated according to ½×length (mm)×width2 (mm2) from the major axis of the tumor. FIG. 7 is a graph showing the relationship between the number of days elapsed after HeLa transplantation and tumor volumes. As can be seen from FIG. 7, HeLa-K was a cancer cell that had a high proliferation rate, while HeLa-B was a cancer cell that had a low proliferation rate. The doubling times of HeLa-K and HeLa-B calculated from FIG. 7 were 4.4 days and 11.0 days, respectively.
  • The HeLa-K- and HeLa-B-transplanted nude mice were administered through the tail veins with [18F]FDG, [11C]choline, [18F]FLT, L- and D-[11C]Met, and L- and D-[11C]MT at 1 MBq ([18F]FDG and [18F]FLT) or 10 MBq ([11C]choline, L- and D-[11C]Met, and L- and D-[11C]MT). After 1 hour of the administration, the mice were decapitated to collect blood and tumor. The radioactivities of the blood and tumor were measured with an automatic gamma counter, their weights were measured, and SUV was determined. Furthermore, to correct the accumulating amounts, SUV (organ)/SUV (blood) was determined by dividing the SUV of the tumor by the SUV of the blood. The obtained results are shown in FIGS. 8 to 9.
  • FIGS. 8 and 9 are respectively diagrams showing the accumulating amount of each compound in blood and tumor. FIG. 8 indicates the accumulating amount by SUV, and FIG. 9 indicates the accumulating amount by SUV (organ)/SUV (blood). As can be seen from the result shown in FIG. 9, D-[11C]MT accumulated more in HeLa-K exhibiting faster proliferation. The difference in the degree of accumulation depending on the difference in proliferation rate was remarkably large for D-[11C]MT as compared with L-[11C]MT and D-[11C]Met. For [18F]FDG and L-[11C]Met, the difference in the degree of accumulation depending on the difference in proliferation rate was not detected.
  • The detection of the difference in proliferation rate that can be achieved depending on the difference in the degree of accumulation suggests that when a tumor proliferation rate was decreased by the manifestation of therapeutic effect, this change can be grasped. Thus, D-[11C]MT is considered to be excellent for the assessment of therapeutic effect on tumor as compared with existing labeled compounds.
    • Example 3 D-[11C]ET Synthesis
  • At first, [11C]ethyl iodide was synthesized in the same way as in the method described in Applied Radiation and Isotopes, Vol. 50, pp. 693-697, 1999.
  • D-tyrosine (1 mg) was supplemented with 10% sodium hydroxide aqueous solution (4.41 μl) and further with dimethyl sulfoxide (0.3 mL) to prepare a material solution. The [11C]ethyl iodide produced by the method was bubbled into the material solution and thereby trapped therein. Then, the reaction vessel was hermetically sealed, and reaction was performed at 80° C. for 3 minutes. The crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 13 minutes was collected and concentrated under reduced pressure to purify D-[11C]ET.
  • HPLC Conditions
  • Column: YMC-Pack ODS-A (10×250 mm) (YMC Co., Ltd.)
  • Mobile phase: ethanol:acetic acid:water=120:25:855
  • Flow rate: 4 mL/min
  • Detection wavelength: 280 nm
  • The residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22-μm membrane filter to obtain a solution of 0.8 to 1.5 GBq of D-[11C]ET in saline (radiochemical purity: 99% or higher).
    • Example 4 D-[18F]FET Synthesis
  • At first, [18F]FCH2CH2OTs was synthesized in the same way as in the method described in Synapse, Vol. 54, pp. 37-45, 2004.
  • D-tyrosine (3 mg) was supplemented with 10% sodium hydroxide aqueous solution (13.2 μl) and further with dimethyl sulfoxide (0.3 mL) to prepare a material solution. The material solution was added to the [18F]FCH2CH2OTs produced by the method. Then, the reaction vessel was hermetically sealed, and reaction was performed at 125° C. for 10 minutes. The crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 9 minutes was collected and concentrated under reduced pressure to purify D-[18F]FET.
  • HPLC Conditions
  • Column: YMC-Pack ODS-A (10×250 mm) (YMC Co., Ltd.)
  • Mobile phase: ethanol:acetic acid:water=100:25:875
  • Flow rate: 4 mL/min
  • Detection wavelength: 280 nm
  • The residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22-μm membrane filter to obtain a solution of 0.5 to 2 GBq of D-[18F]FET in saline (radiochemical purity: 99% or higher).
    • Example 5 D-[18F]FPT Synthesis
  • At first, [18F]FCH2CH2CH2OTs was synthesized with TsOCH2CH2CH2OTs as a material in the same way as in the method described in Synapse, Vol. 54, pp. 37-45, 2004.
  • D-tyrosine (3 mg) was supplemented with 10% sodium hydroxide aqueous solution (13.2 μl) and further with dimethyl sulfoxide (0.3 mL) to prepare a material solution. The material solution was added to the [18F]FCH2CH2CH2OTs produced by the method. Then, the reaction vessel was hermetically sealed, and reaction was performed at 125° C. for 10 minutes. The crude product was subjected to HPLC under conditions described below. A radioactive peak fraction with a retention time of 17 minutes was collected and concentrated under reduced pressure to purify D-[18F]FPT.
  • HPLC Conditions
  • Column: YMC-Pack ODS-A (10×250 mm) (YMC Co., Ltd.)
  • Mobile phase: ethanol:acetic acid:water=120:25:855
  • Flow rate: 4 mL/min
  • Detection wavelength: 280 nm
  • The residue obtained by the concentration was redissolved in 3 mL of saline and sterilized by filtration with a 0.22-μm membrane filter to obtain a solution of 0.2 to 0.6 GBq of D-[18F]FPT in saline (radiochemical purity: 99% or higher).
    • Comparative Example 8 O—[11C]ethyl-L-tyrosine (L-[11C]ET) Synthesis
  • L-[11C]ET was synthesized in the same way as in the method described in Example 3 except that L-tyrosine was used as a material instead of D-tyrosine.
    • Comparative Example 9 O—[18F]fluoroethyl-L-tyrosine (L-[18F]FET) Synthesis
  • L-[18F]FET was synthesized in the same way as in the method described in Example 4 except that L-tyrosine was used as a material instead of D-tyrosine.
    • Comparative Example 10 O—[18F]fluoropropyl-L-tyrosine (L-[18F]FPT) Synthesis
  • L-[18F]FPT was synthesized in the same way as in the method described in Example 5 except that L-tyrosine was used as a material instead of D-tyrosine.
    • Test Example 4 Measurement of Organ Distribution in Cancer-Bearing Mice
  • The organ distribution of the compounds of Examples 3 to 5 and Comparative Examples 8 to 10 was measured in the same way as in Test Example 1. The obtained results are shown in FIGS. 10 to 12.
  • FIG. 10 is a diagram showing the accumulating amounts of L- and D-[11C]ET in each organ. The accumulating amount is indicated by SUV (organ)/SUV (blood). As can be seen from this result, the accumulation of L- and D-[11C]MT was observed in the tumor, whereas their accumulation was low in the normal tissues except for the pancreas and was specific to the tumor. Furthermore, the D-form had a similar value of SUV (organ: tumor)/SUV (blood) comparable to that of the L-form. Moreover, the ratio of accumulation to the pancreas to accumulation to the tumor indicated by SUV (organ)/SUV (blood) was shown to be lower in the D-form than in the L-form. Thus, it was suggested that the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
  • FIG. 11 is a diagram showing the accumulating amounts of L- and D-[18F]FET in each organ. The accumulating amount is indicated by SUV (organ)/SUV (blood). As can be seen from this result, the accumulation of L- and D-[18F]FET was observed in the tumor, whereas their accumulation was low in the normal tissues except for the pancreas and was specific to the tumor. Furthermore, the D-form had a higher value of SUV (organ: tumor)/SUV (blood) than the L-form and was shown to have particularly high specificity to the tumor. Moreover, the ratio of accumulation to the pancreas to accumulation to the tumor indicated by SUV (organ)/SUV (blood) was shown to be lower in the D-form than in the L-form. Thus, it was suggested that the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
  • FIG. 12 is a diagram showing the accumulating amounts of L- and D-[18F]FPT in each organ. The accumulating amount is indicated by SUV (organ)/SUV (blood). As can be seen from this result, the accumulation of L- and D-[18F]FPT was observed in the tumor, whereas their accumulation was low in the normal tissues except for the pancreas and bone and was specific to the tumor. Furthermore, the D-form had a similar value of SUV (organ: tumor)/SUV (blood) comparable to that of the L-form. Moreover, the ratio of accumulation to the pancreas to accumulation to the tumor indicated by SUV (organ)/SUV (blood) was shown to be lower in the D-form than in the L-form. Thus, it was suggested that the D-form can be utilized as an excellent tumor diagnostic agent as compared with the L-form.
    • Test Example 5 Relationship Between Tumor Proliferation Rate and Degree of Accumulation of Labeled Compound for Positron Imaging
  • HeLa-K- and HeLa-B-transplanted nude mice were administered through the tail veins with L- and D-[11C]ET, L- and D-[18F]FMT, L- and D-[18F]FET, and L- and D-[18F]FPT at 10 MBq (L- and D-[11C]ET) or 1 MBq (the others). After 1 hour of the administration, the mice were decapitated to collect blood and tumor. The radioactivities of the blood and tumor were measured with an automatic gamma counter, their weights were measured, and SUV was determined. Furthermore, to correct the accumulating amounts, SUV (organ)/SUV (blood) was determined by dividing the SUV of the tumor by the SUV of the blood. The obtained result is shown in FIG. 13.
  • FIG. 13 is a diagram showing the accumulating amount of each compound in tumor. The accumulating amount is indicated by SUV (organ)/SUV (blood). As can be seen from this result, all of the compounds accumulated more in HeLa-K exhibiting faster proliferation. The difference in the degree of accumulation of D-[18F]FMT depending on the difference in proliferation rate was remarkably large as compared with D-[18F]FMT. Thus, these compounds are considered to be excellent for the assessment of therapeutic effect on tumor as compared with existing labeled compounds.
    • INDUSTRIAL APPLICABILITY
  • The present invention allows for tumor diagnosis by PET and particularly allows for the early assessment of the therapeutic effect of radiotherapy and so on.

Claims (6)

1. A radioactive tyrosine derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof:
Figure US20090098048A2-20090416-C00005
wherein R1 represents a group selected from the group consisting of —11CH3, —11CH2CH3, —CH2 18F, and —CH2CH2CH2 18F.
2. A method for producing a radioactive tyrosine derivative or a pharmaceutically acceptable salt thereof according to claim 1, comprising alkylating or fluoroalkylating D-tyrosine or a pharmaceutically acceptable salt thereof.
3. A labeled agent for positron imaging consisting of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof:
Figure US20090098048A2-20090416-C00006
wherein R1 represents a group selected from the group consisting of —11CH3, —11CH2CH3, —CH2 18F, —CH2CH2 18F, and —CH2CH2CH2 18F.
4. An agent for assessing grade of tumor malignancy consisting of a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof.
5. A method for detecting tumor comprising:
a step of administering a radioactive tyrosine derivative represented by the formula (II) or a pharmaceutically acceptable salt thereof to a subject;
a step of measuring a radiation dose of each tissue of the subject; and
a detection step of detecting a tissue with a relatively large radiation dose as a tumor tissue through comparison of the radiation dose of each tissue.
6. A method for detecting tumor according to claim 5, wherein at the detection step, a tissue with a relatively large radiation dose with respect to the radiation dose of blood is detected as a tumor tissue.
US11/597,557 2004-05-28 2005-05-25 Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor Active 2031-08-04 US9388122B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPP2004-159941 2004-05-28
JP2004-159941 2004-05-28
JP2004159941 2004-05-28
PCT/JP2005/009530 WO2005115971A1 (en) 2004-05-28 2005-05-25 Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor

Publications (3)

Publication Number Publication Date
US20080138281A1 US20080138281A1 (en) 2008-06-12
US20090098048A2 true US20090098048A2 (en) 2009-04-16
US9388122B2 US9388122B2 (en) 2016-07-12

Family

ID=35450805

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/597,557 Active 2031-08-04 US9388122B2 (en) 2004-05-28 2005-05-25 Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor

Country Status (5)

Country Link
US (1) US9388122B2 (en)
EP (1) EP1749815B1 (en)
JP (1) JP4842123B2 (en)
CN (1) CN1950329B (en)
WO (1) WO2005115971A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9839701B2 (en) 2013-02-12 2017-12-12 Osaka University Aromatic amino acid derivative and positron emission topography (PET) probe using the same

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2114873E (en) * 2006-12-26 2013-05-06 Lantheus Medical Imaging Inc N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation
DE102009035647A1 (en) * 2009-04-03 2010-10-07 Siemens Aktiengesellschaft Method for generating a radiopharmaceutical
JP5237880B2 (en) * 2009-04-30 2013-07-17 Ｊｆｅテクノス株式会社 Method and apparatus for producing labeled compound for PET using microchip
CA2789286A1 (en) * 2010-02-08 2011-08-11 Piramal Imaging Sa F18-tyrosine derivatives for imaging bone metastases
MX367382B (en) * 2010-05-11 2019-08-19 Lantheus Medical Imaging Inc Compositions, methods and systems for the synthesis and use of imaging agents.
CA2840768A1 (en) * 2011-06-30 2013-01-03 Piramal Imaging Sa Direct synthesis of 18f-fluoromethoxy compounds for pet imaging and new precursors for direct radiosynthesis of protected derivatives of o-([18f]fluoromethyl) tyrosine
EP2540710A1 (en) * 2011-06-30 2013-01-02 Bayer Schering Pharma Aktiengesellschaft New precursors for direct radiosynthesis of protected derivatives of O-([18F]Fluoromethyl) tyrosine
KR20190015765A (en) 2011-09-09 2019-02-14 랜티우스 메디컬 이메징, 인크. Compositions, methods, and systems for the synthesis and use of imaging agents
AU2017368234B2 (en) 2016-12-02 2022-02-24 The Board Of Regents Of The University Of Oklahoma Imaging agents and methods of use
JP2022024272A (en) 2020-07-14 2022-02-09 浜松ホトニクス株式会社 Diagnostic agent for pancreatic function
JP2022072167A (en) 2020-10-29 2022-05-17 浜松ホトニクス株式会社 Agent for detecting interaction between tissues and organs
JP2022104118A (en) 2020-12-28 2022-07-08 浜松ホトニクス株式会社 Method for evaluating mitochondrial function in organ and tissue other than kidney of subject

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9839701B2 (en) 2013-02-12 2017-12-12 Osaka University Aromatic amino acid derivative and positron emission topography (PET) probe using the same

Also Published As

Publication number Publication date
WO2005115971A1 (en) 2005-12-08
US9388122B2 (en) 2016-07-12
EP1749815B1 (en) 2017-06-21
US20080138281A1 (en) 2008-06-12
JPWO2005115971A1 (en) 2008-03-27
EP1749815A4 (en) 2010-05-26
CN1950329B (en) 2010-05-05
JP4842123B2 (en) 2011-12-21
EP1749815A1 (en) 2007-02-07
CN1950329A (en) 2007-04-18

Similar Documents

Publication Publication Date Title
US9388122B2 (en) Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor
TWI406674B (en) Method for manufacturing diagnostic radiographic diagnostic agents
US20070081941A1 (en) F-18 Labeled Amino Acid Analogs
US10259781B2 (en) Imaging agents
BRPI0821241B1 (en) PROCESS FOR THE PRODUCTION OF AN ORGANIC COMPOUND MARKED WITH RADIOACTIVE FLUORIDE
ES2882111T3 (en) Lactate derivative with [18F] marker as a radiotracer for PET
Minn et al. Imaging of tumor hypoxia to predict treatment sensitivity
KR20150004940A (en) Radioactive diagnostic imaging agent
US11426395B2 (en) PSMA inhibitor derivatives for labelling with 99mTc via HYNIC, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer diagnostics
US20100056826A1 (en) Radioactive diagnostic imaging agent
JP5404405B2 (en) Weakly basic 2-nitroimidazole for noninvasive detection of tissue hypoxia
US20110300073A1 (en) 18f-labelled three-and four-carbon acids for pet imaging
EP3216796B1 (en) Phosphonium compound and production method therefor
US9814789B2 (en) Radiopharmaceutical products for diagnosis and therapy of adrenal carcinoma
US10081630B2 (en) Radioactive halogen-labeled pyrido [1,2-A] benzimidazole derivative compound
US20100150835A1 (en) Synthesis of [18F] Fluoromethyl Benzene Using Benzyl Pentafluorobenzenesulfonate
US20240024519A1 (en) Radiopharmaceutical compositions of copper for targeted molecular imaging
JP2023009974A (en) Compound comprising boron and iodine or salt thereof, and their use
WO2004071505A2 (en) Radiolabelled d-amino acids for use in diagnosis with spect and pet and systemic radionuclide therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: HAMAMATSU PHOTONICS K.K., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SATO, KENGO;TSUKADA, HIDEO;REEL/FRAME:020307/0305

Effective date: 20061218

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8